This on-demand case-based webinar is the first of a three-part series on ROS1 being released in the summer of 2017. The focus for this webinar is on new diagnostic strategies for advanced non-small cell lung cancer (NSCLC).
The activity offers 1 CME, CMLE, or SAMs CME credit.
New therapies based on molecular biomarkers signify promising advances for those patients with NSCLC who have not responded to traditional chemotherapy treatment protocols. One such advance is the identification of therapeutic agents that target the ROS1 gene rearrangement. National Cancer Center Network (NCCN) 2015 Guidelines recommend ROS1 testing for targeted therapies in all appropriate patients with advanced lung cancer. In addition, the advent of targeted therapies has increased the awareness of the laboratory team’s crucial role in the management of lung cancer, and the direct impact testing, interpretation, and diagnosis of biomarkers has on patient therapies.
However, pathologists and laboratory professionals must communicate effectively with their colleagues to ensure the accurate interpretation and management of ROS1 rearrangements in NSCLC. Clinical teams also lack clarity on the role of pathological testing in guiding selection of optimal treatment regimens. Clear communication and reporting of ROS1 results between the laboratory and the oncologist is necessary to ensure proper treatment.
In this webinar, participants will learn the pros and cons of fluorescence in-situ hybridization (FISH), immunohistochemistry (IHC), reverse transcription polymerase chain reaction (RT-PCR), and next-generation sequencing (NGS) testing for ROS1 so that they are better equipped to optimize the implementation of these tests and reporting of results.
Learning Objectives:
-
Identify the pros and cons of FISH, IHC, RT-PCR, and NGS ROS1 testing for ROS1
-
Analyze and discuss problem-based NSCLC ROS1 laboratory-testing case studies to identify and recommend optimal work process to achieve specimen adequacy, interpretation, and reporting
The American Society for Clinical Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation Statement
The ASCP designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.
For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a .m. to 6 p.m. Eastern Time
Method of Participation
To complete the activity and receive credit, the participant must complete the online course. CME certificates will be provided on-line.
Funded by an independent educational grant from Pfizer.